Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.59 |
| ▸ | APP | P05067 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CDK8 | P49336 | 2/20 | 0.53 |
| ▸ | CDK9 | P50750 | 2/20 | 0.53 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191752 | 0.91 | PARP1 (0.58) | PARP1PARP2APPMAOBCYP19A1 | |
| SCHEMBL3173373 | 0.88 | CYP1B1 (0.54) | PARP1PARP2APPALDH1A1MEN1 | |
| SCHEMBL3192458 | 0.87 | PDE5A (0.53) | PARP1PARP2CDK8PDE5AESR1 | |
| SCHEMBL3184919 | 0.87 | PARP1 (0.57) | PARP1PARP2PDE5AESR1PDE4D | |
| SCHEMBL3192344 | 0.85 | DYRK1A (0.51) | PARP1PARP2APPALDH1A1MEN1 | |
| SCHEMBL19353997 | 0.84 | PARP1 (0.65) | PARP1PARP2APPMAOBCYP19A1 | |
| SCHEMBL19354126 | 0.84 | PARP1 (0.60) | PARP1PARP2APPMAOBCYP19A1 | |
| SCHEMBL31655473 | 0.82 | PDE5A (0.67) | APPCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3183521 | 0.82 | PDE5A (0.67) | APPCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3180019 | 0.81 | PDE5A (0.55) | CYP3A4MAPTCYP2D6ADORA3PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | claimed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | claimed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | claimed |
| CN-102018698-B | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-07-02 | — | — | CN | disclosed |
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | PARP1 1859/4885PARP2 2386/4885APP 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.